Germline genetics and different responses to different types of ADT

Three articles in the October 12 issue of JAMA Oncology address the fact that a very specific germline mutation to the so-called HSD3B1 gene affects response to standard forms of initial androgen deprivation therapy and related factors. … READ MORE …

Individualizing precision therapy for advanced prostate cancer

There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be “tailor-made” for individualized, precision cancer therapy. … READ MORE …

The accurate assessment of risk profiles among high-risk prostate cancer patients

A key question in management of prostate cancer is the risk that a particular patient has disease — at the time of diagnosis — that will progress over time to become metastatic. The ability to answer this question with accuracy is fundamental to the need for aggressive, early treatment. … READ MORE …

Polygenicity, risk for prostate cancer, and the need for regular testing

A new study in the British Journal of Cancer suggests that knowledge of the presence of low or high numbers of known prostate cancer-related genes (polygenicity) “could” be helpful in determining which patients actually need regular testing for risk of prostate cancer. … READ MORE …

The complexity of assessment of prostate cancer risk

A new study just published online in the journal Cancer Discovery has helped to clarify — or perhaps “clarify” is the wrong word — just how complex risk for prostate cancer really is. … READ MORE …

A compound genetic/genomic and microenvironmental risk classification for localized prostate cancer

As we become more knowledgeable about the underlying genetic and other factors that affect the risk for, and the risk for progression of, apparently localized prostate cancer, we also become more able to predict such risks … but this is a very complex topic. … READ MORE …

Gene signatures, prognosis, and treatment of men with CRPC

We are clearly getting closer to being able to make accurate projections about which forms of castration-resistant prostate cancer (CRPC) are really aggressive and need immediate, aggressive therapeutic intervention and which are likely to progress more slowly (over a period of years). However, this is only the beginning of the story. … READ MORE …

Molecular signatures and prediction of poor prostate cancer outcomes over time

An article by Markert et al., just published on line in the Proceedings of the National Academy of Sciences, suggests that microarray analysis of messenger ribonucleic acid (mRNA) expression in prostate cancer tumors may be an independent indicator of the aggressiveness of prostate cancers in individual patients. … READ MORE …